NGM Phase IIb NASH Failure Could Darken Competitors’ Prospects
Executive Summary
NGM will not proceed with a Phase III study in F2/F3 NASH following failure to show fibrosis benefit in Phase IIb. Analysts say this setback could portend disappointing readouts for other NASH players.
You may also be interested in...
NGM’s Second Phase II Miss Raises Questions For Option Deal With Merck
NGM said a Merck-partnered C3 inhibiting antibody has failed a Phase II study in geographic atrophy, after the biotech’s wholly owned NASH candidate missed in a Phase IIb study in 2021.
Deal Watch: Pfizer Invests In Spero, Parexel Trades Hands
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
89bio Hopes Akero’s Success In Cirrhotic NASH Is Positive For FGF21 Class
Analysts say the cirrhosis-reversing benefit seen with Akero’s efruxifermin portends well for the entire class, and that 89bio might differentiate on safety, tolerability and dosing frequency.